Lupron_retards_proliferation_of_ovarian_epithelial_tumor_cells_cultured_in_serum-free_medium._Some_patients_with_recurrent_ovarian_epithelial_cancer_respond_favorably_to_treatment_with_GnRH_agonists._This_effect_was_proposed_to_be_mediated_by_suppression_of_pituitary_gonadotropin_release._The_present_in_vitro_study_investigated_effects_of_human_gonadotropin_(Pergonal_LH/FSH,_1:1)_and_Lupron,_a_GnRH_agonist,_on_proliferation_of_an_ovarian_cancer_cell_line,_2774,_which_is_estrogen_receptor_negative_and_grows_well_in_serum-free,_defined_medium._Pergonal,_10_IU/mL_or_30_IU/mL,_did_not_enhance_cell_proliferation,_which_argues_against_stabilization_of_ovarian_tumors_in_vivo_due_to_decreased_serum_gonadotropin._Lupron,_1.4_micrograms/mL_and_140_micrograms/mL,_retarded_cell_division_by_day_6-8_of_culture,_in_a_dose-dependent_manner._Flow_cytometric_cell_cycle_phase_DNA_analysis_demonstrated_Lupron_caused_a_reversible_5-6%_increase_in_the_portion_of_cells_in_rest_phase,_G0/G1,_compared_to_controls_during_log_growth,_and_a_corresponding_decrease_in_the_portion_of_cells_in_DNA_synthesis,_S_phase._However,_long-term_culture,_3_weeks,_with_Lupron_failed_to_arrest_cells_in_G0/G1,_and_experimental_cultures_plateaued_at_cell_number_similar_to_control_cultures._We_conclude_Lupron's_effect_on_ovarian_cancer_cell_proliferation_is_independent_of_gonadotropin_and_steroid,_involves_a_cell_cycle_regulatory_event,_and_duration_of_benefit_observed_in_vivo_for_some_patients_may_be_related_to_total_tumor_volume_at_the_time_of_treatment.